BR112016018099B8 - Compostos funcionalizados de benzopiranos e uso dos mesmos - Google Patents

Compostos funcionalizados de benzopiranos e uso dos mesmos

Info

Publication number
BR112016018099B8
BR112016018099B8 BR112016018099A BR112016018099A BR112016018099B8 BR 112016018099 B8 BR112016018099 B8 BR 112016018099B8 BR 112016018099 A BR112016018099 A BR 112016018099A BR 112016018099 A BR112016018099 A BR 112016018099A BR 112016018099 B8 BR112016018099 B8 BR 112016018099B8
Authority
BR
Brazil
Prior art keywords
functionalized
benzopyran compounds
present
compounds
benzopyran
Prior art date
Application number
BR112016018099A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016018099B1 (pt
BR112016018099A2 (pt
Inventor
Heaton Andrew
Brown David
Kelly Graham
Original Assignee
Novogen ltd
Kazia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd, Kazia Therapeutics Ltd filed Critical Novogen ltd
Publication of BR112016018099A2 publication Critical patent/BR112016018099A2/pt
Publication of BR112016018099B1 publication Critical patent/BR112016018099B1/pt
Publication of BR112016018099B8 publication Critical patent/BR112016018099B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016018099A 2014-02-07 2015-02-05 Compostos funcionalizados de benzopiranos e uso dos mesmos BR112016018099B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US61/937,368 2014-02-07
US201461987323P 2014-05-01 2014-05-01
US61/987,323 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Publications (3)

Publication Number Publication Date
BR112016018099A2 BR112016018099A2 (pt) 2017-08-08
BR112016018099B1 BR112016018099B1 (pt) 2022-10-11
BR112016018099B8 true BR112016018099B8 (pt) 2023-01-17

Family

ID=53777071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018099A BR112016018099B8 (pt) 2014-02-07 2015-02-05 Compostos funcionalizados de benzopiranos e uso dos mesmos

Country Status (24)

Country Link
US (2) US9701655B2 (enExample)
EP (1) EP2953938B1 (enExample)
JP (1) JP6570042B2 (enExample)
KR (1) KR102395543B1 (enExample)
CN (2) CN108484559A (enExample)
AU (1) AU2015213484B2 (enExample)
BR (1) BR112016018099B8 (enExample)
CA (1) CA2936012C (enExample)
CL (1) CL2016001937A1 (enExample)
DK (1) DK2953938T3 (enExample)
ES (1) ES2643407T3 (enExample)
IL (1) IL241515B (enExample)
LT (1) LT2953938T (enExample)
MX (1) MX368063B (enExample)
MY (1) MY195739A (enExample)
NZ (1) NZ711603A (enExample)
PH (1) PH12016501422B1 (enExample)
PL (1) PL2953938T3 (enExample)
PT (1) PT2953938T (enExample)
RU (1) RU2676766C2 (enExample)
SA (1) SA516371583B1 (enExample)
SG (2) SG11201604490SA (enExample)
SI (1) SI2953938T1 (enExample)
WO (1) WO2015117202A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201604490SA (en) * 2014-02-07 2016-07-28 Novogen ltd Functionalised benzopyran compounds and use thereof
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
US10265294B2 (en) * 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
CN106943397B (zh) * 2017-03-01 2020-08-04 浙江大学 雄激素受体拮抗剂及其应用
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
US20230233519A1 (en) * 2020-06-11 2023-07-27 Mei Pharma, Inc. Combination therapies
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof
CN118005594B (zh) * 2023-05-24 2024-10-29 内蒙古大学 3-羟基苯并二氢吡喃衍生物的合成及其抗肿瘤活性

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
CA2208868A1 (en) 1995-01-13 1996-07-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
HUP9800521A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis
AU4329196A (en) 1995-01-20 1996-08-07 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
KR19980701549A (ko) 1995-01-20 1998-05-15 슈타르 피아 퇴행성 뇌질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 이용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders)
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
IL124882A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
CA2270113A1 (en) * 1996-10-28 1998-05-07 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2001502704A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は処置において有用な新規ｃｉｓ―３，４―クロマン誘導体の新規の（―）―鏡像異性体
AU5550298A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
ZA98681B (en) 1997-01-29 1998-07-29 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibition senescense-associated motor impairment
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
EP1115398B1 (en) * 1998-09-23 2010-05-05 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
WO2002030407A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
JP4256679B2 (ja) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
US20060141591A1 (en) 2003-06-04 2006-06-29 Youichi Kyuuko Method for producing optically active chroman-carboxylate
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
WO2006032086A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
JP4976649B2 (ja) 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP2407462B1 (en) 2004-09-21 2014-07-30 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
ES2377073T3 (es) * 2004-09-21 2012-03-22 Marshall Edwards, Inc. Derivados de cromano sustituidos, medicamentos y utilización en terapia
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
WO2007096362A1 (en) 2006-02-21 2007-08-30 Trigen Limited Heterocyclic compounds and their use in the treatment of cardiovascular disease
EP2084141A4 (en) 2006-10-30 2010-07-21 Novogen Res Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
US20120039917A1 (en) 2008-08-29 2012-02-16 Alan James Husband Immunomodulating activities
EP2362773A4 (en) 2008-10-22 2012-05-09 Novogen Res Pty Ltd METHOD FOR TRIGGERING PROGRAMMED CELL DEATH
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
EP2635121B1 (en) * 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
US20120251630A1 (en) 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids
US20150018566A1 (en) * 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
CN104870438A (zh) 2012-06-07 2015-08-26 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
SG11201604490SA (en) * 2014-02-07 2016-07-28 Novogen ltd Functionalised benzopyran compounds and use thereof

Also Published As

Publication number Publication date
KR102395543B1 (ko) 2022-05-09
SG11201604490SA (en) 2016-07-28
US9701655B2 (en) 2017-07-11
WO2015117202A1 (en) 2015-08-13
EP2953938B1 (en) 2017-08-02
PH12016501422B1 (en) 2022-02-16
BR112016018099B1 (pt) 2022-10-11
RU2016133731A3 (enExample) 2018-08-08
PH12016501422A1 (en) 2016-08-31
EP2953938A1 (en) 2015-12-16
BR112016018099A2 (pt) 2017-08-08
CA2936012A1 (en) 2015-08-13
AU2015213484B2 (en) 2015-11-05
LT2953938T (lt) 2017-10-10
SA516371583B1 (ar) 2019-04-18
CL2016001937A1 (es) 2017-01-20
SI2953938T1 (en) 2018-01-31
JP2017507175A (ja) 2017-03-16
RU2676766C2 (ru) 2019-01-11
SG11201506988TA (en) 2015-10-29
PT2953938T (pt) 2017-10-09
PL2953938T3 (pl) 2017-12-29
CA2936012C (en) 2023-03-07
MX368063B (es) 2019-09-18
AU2015213484A1 (en) 2015-09-17
CN105980372A (zh) 2016-09-28
IL241515A0 (en) 2015-11-30
CN108484559A (zh) 2018-09-04
IL241515B (en) 2019-06-30
JP6570042B2 (ja) 2019-09-04
RU2016133731A (ru) 2018-03-12
MY195739A (en) 2023-02-08
ES2643407T3 (es) 2017-11-22
KR20160110427A (ko) 2016-09-21
MX2016010137A (es) 2017-02-15
US20160340329A1 (en) 2016-11-24
NZ711603A (en) 2017-05-26
US10370349B2 (en) 2019-08-06
HK1218914A1 (en) 2017-03-17
EP2953938A4 (en) 2016-08-10
US20180141925A1 (en) 2018-05-24
CN105980372B (zh) 2018-05-08
DK2953938T3 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
BR112016018099B8 (pt) Compostos funcionalizados de benzopiranos e uso dos mesmos
EP3507753A4 (en) SENDING VIRTUAL CURRENCY TRANSACTION SYSTEM
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
CL2016002514A1 (es) Uso de dianhidrogalactilol y análogos o derivados del mismo para tratar células no pequeñas de carcinoma de pulmón y cáncer de ovarios
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
SI3134124T1 (sl) Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
HUE052223T2 (hu) IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018008103A2 (pt) análogos de celastrol
SG11201802915WA (en) Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
BR112017025255A2 (pt) métodos, produto, produto de programa de computador, sistema, e composições farmacêuticas estimulante e inibidora para uso no tratamento ou prevenção do câncer de próstata
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
HUE059448T2 (hu) Liposzómás készítmény, rák kezelésében való alkalmazásra
BR112016026545A2 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
HUE055132T2 (hu) Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2701 DE 11/10/2022, QUANTO AO ITEM (73) ENDERECO DO TITULAR.

B25D Requested change of name of applicant approved

Owner name: KAZIA THERAPEUTICS LIMITED (AU)

B25G Requested change of headquarter approved

Owner name: KAZIA THERAPEUTICS LIMITED (AU)

B25G Requested change of headquarter approved

Owner name: KAZIA THERAPEUTICS LIMITED (AU)

B25A Requested transfer of rights approved

Owner name: VIVESTO AB (PUBL) (SE)